β抑制剂与HFpEF患者全因死亡率降低有关
Joseph Ibrahim1, Carly Fabrizio2, Ahmet Sezer1,3
1Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
概括
贝塔阻塞剂 (BB) 与心力衰竭患者的死亡率降低有关,心力衰竭患者的死亡率降低,心力衰竭患者的死亡率降低. 当与其他心力衰竭药物相结合时,这种益处仍然存在,这表明BB可能仍然有益.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 关于β阻塞剂 (BB) 在保留喷射分数 (HFpEF) 的心力衰竭中有效性的证据是不确定的.
- 这种不确定性促使人们考虑在HFpEF患者中中止BBs.
研究的目的:
- 追溯分析β阻断剂使用与HFpEF患者全因死亡率之间的关联.
主要方法:
- 一个单一中心的回顾性队列研究包括20206名左心室喷射率 (EF) ≥50%的患者,因无补偿心力衰竭住院治疗.
- 分析了30天,1年和3年的生存时间.
- 二次分析检查了额外指示 (高血压,冠状动脉疾病,心房) 的BBs,并将死亡率与螺旋或ACEi/ARBs进行了比较.
主要成果:
- β抑制剂与30天,1年和3年的全因死亡率显著降低相关 (p < 0.0001).
- 这种关联得到了倾向性得分匹配分析的证实.
- 3年后,BBs与螺旋或ACEi/ARBs相结合显示出显著的死亡率降低.
结论:
- 贝塔抑制剂的使用与最近因心力衰竭去补偿而住院的HFpEF患者的死亡率降低有关.
- 观察到BBs的生存益处,即使在与螺旋,ACEi/ARB或心房的患者一起使用时也是如此.
- 这些发现表明,在等待大型随机试验的情况下,需要重新考虑在耐受良好的患者中退出BB.
相关概念视频
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
783
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
783
01:28Antihypertensive Drugs: Types of β-Blockers
657
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
657
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
442
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
442
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
592
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
592